United Therapeutics (UTHR) said Tuesday that a phase 3 study evaluating the use of nebulized Tyvaso to treat idiopathic pulmonary fibrosis, of IPF, has reached full enrollment.
The 598-patient Teton 1 study is part of three-study clinical trial program assessing the use of inhaled treprostinil in IPF and a similar condition of progressive pulmonary fibrosis, the biotechnology company said.
Enrollment for the Teton 2 trial, which is evaluating the use of Tyvaso in IPF in patients outside the US and Canada was completed in July last year, with top-line data expected in the second half of this year, it said.
If both studies are successful, United Therapeutics said the data will be used to support a filing for the US Food and Drug Administration's approval to add IPF to the labeled indications for nebulized Tyvaso.
Price: 351.22, Change: -3.36, Percent Change: -0.95
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。